Ambrx Biopharma Cayman, Inc. Deferred Tax Assets, Valuation Allowance USD 2020 - 2022

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Ambrx Biopharma Cayman, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from 2020 to 2022.
  • Ambrx Biopharma Cayman, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2022 was $81.7 M, a 33.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $81.7 M +$20.6 M +33.8% Dec 31, 2022 10-K 2023-03-30
Q4 2021 $61 M +$17.6 M +40.5% Dec 31, 2021 10-K 2023-03-30
Q4 2020 $43.4 M Dec 31, 2020 20-F 2022-04-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.